menu
    • menu

    Company profile for Ribon Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ribon is pioneering the development of first-in-class therapeutics targeting enzyme families that are activated under cellular stress conditions. We explore novel areas of disease biology and use our expertise in drug discovery to develop new and effective treatments for patients with high unmet need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ribon TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    35 Cambridgepark Drive Cambridge, MA 02140
    Telephone
    Telephone
    617-914-8700
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ribontx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ribon-therapeutics
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ribon rids preclinical work, trims staff to focus on two PARP inhibitors
    Ribon rids preclinical work, trims staff to focus on two PARP inhibitors

    28 Jul 2023

    // Kyle LaHucik ENDPTS

    https://endpts.com/ribon-therapeutics-rids-preclinical-work-trims-staff-to-focus-on-two-clinical-parp-inhibitors/

    Kyle LaHucik ENDPTS
    28 Jul 2023
    Share Share
    Ribon Doses First Patient in Phase 1 Clinical Study with RBN-3143
    Ribon Doses First Patient in Phase 1 Clinical Study with RBN-3143

    09 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230309005186/en

    BUSINESSWIRE
    09 Mar 2023
    Share Share
    Pfizer invests in Ribon Therapeutics; Argenx gets PDUFA date extension
    Pfizer invests in Ribon Therapeutics; Argenx gets PDUFA date extension

    30 Jan 2023

    // Tyler Patchen ENDPTS

    https://endpts.com/pfizer-invests-in-ribon-therapeutics-argenx-gets-pdufa-date-extension/

    Tyler Patchen ENDPTS
    30 Jan 2023
    Share Share
    Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer
    Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer

    30 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230130005182/en

    BUSINESSWIRE
    30 Jan 2023
    Share Share
    Ribon Announces Acquisition of Pre-Clinical CD38 Program by Boehringer
    Ribon Announces Acquisition of Pre-Clinical CD38 Program by Boehringer

    29 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221129005153/en

    BUSINESSWIRE
    29 Nov 2022
    Share Share
    Ribon Therapeutics Announces Presentation of Preclinical Data on RBN-3143
    Ribon Therapeutics Announces Presentation of Preclinical Data on RBN-3143

    06 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220906005129/en

    BUSINESSWIRE
    06 Sep 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search